{"id":"W3088602042","doi":"10.1016/j.annonc.2020.08.2250","title":"LBA4 IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; PTEN; Prostate cancer; Internal medicine; Placebo; Androgen deprivation therapy; Prednisone; Gastroenterology; Asymptomatic; Clinical endpoint; Cancer; Urology; Oncology; Clinical trial; PI3K/AKT/mTOR pathway; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001260729,0.002061041,0.002235382,0.0006620125,0.0004266221,0.001608468,0.001497566,0.001392651,0.01080554],"category_scores_gemma":[0.0009554714,0.0008106654,0.00245097,0.0006451323,0.001189705,0.0009178708,0.0004611237,0.005062609,0.00229302],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001071539,"about_ca_system_score_gemma":0.001944151,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002799932,"about_ca_topic_score_gemma":0.007396559,"domain_scores_codex":[0.9996778,0.0001246129,0.00001258371,0.00005908316,0.00003131885,0.0000946214],"domain_scores_gemma":[0.9995135,0.00007454448,0.00008850882,0.00004235319,0.00003032234,0.0002508251],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8593908,0.02872521,0.001572052,0.001395724,0.002607424,0.00008773884,0.0001577237,0.001851445,0.01588771,0.0005418452,0.006291215,0.08149111],"study_design_scores_gemma":[0.8201947,0.1696287,0.003555002,0.0000690318,0.0009748847,0.0001271876,0.00006492383,0.0009113764,0.001348309,0.0003371953,0.002750826,0.00003788497],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9746681,0.007318503,0.001011834,0.001202396,0.0006805392,0.002827103,0.004016532,0.0007084632,0.007566546],"genre_scores_gemma":[0.9694152,0.005511235,0.002201017,0.001888935,0.0004432217,0.002879543,0.006196826,0.0001277074,0.01133632],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01080554,"threshold_uncertainty_score":0.03614813,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1923641444501005,"score_gpt":0.4583087087033202,"score_spread":0.2659445642532197,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}